바이오

Biopharmaceutical

보기
Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degen 2015.12

Osteoarthritis Cartilage 2015 Dec;23(12):2109-18

Mont M. et al.



Abstract
The aim of this study was to preliminarily evaluate the efficacy and outcomes of injectable genetically engineered chondrocytes virally transduced with TGF-β1 (GEC-TGF-β1) compared to placebo.



Reference: http://www.ncbi.nlm.nih.gov/pubmed/26188189